AST Levels Explained: What Your Number Changes About Your Treatment

What AST Actually Measures

AST is an enzyme found inside liver cells, heart muscle, skeletal muscle, and red blood cells. When those cells are injured or destroyed, they release AST into the bloodstream. Your provider measures it alongside ALT (alanine aminotransferase) to get a clearer picture of whether liver cells specifically are under stress, or whether the signal is coming from another tissue.

The ratio of AST to ALT matters as much as either number alone. An AST:ALT ratio above 2:1 points toward alcoholic liver disease, while a ratio below 1 is more consistent with nonalcoholic fatty liver disease (NAFLD) or viral hepatitis. Your clinician will read your single number inside this paired context.

Why the "Normal Range" Is Not One-Size-Fits-All

Reference ranges vary slightly between laboratories, but most U.S. Labs set the upper limit for adult women between 35 and 40 U/L. Some endocrinology groups have argued those cutoffs were derived from populations that included people with undiagnosed metabolic liver disease, meaning the true healthy upper limit for women may be closer to 25 U/L. The American Association for the Study of Liver Diseases (AASLD) has acknowledged that traditional reference ranges may under-detect early liver injury in lean women.

How Sex Hormones Shift Your Baseline

Estrogen has a protective effect on the liver. Before menopause, women tend to have lower baseline AST values than men of the same age. After menopause, that advantage narrows. One large epidemiological analysis found that postmenopausal women showed AST values approximately 15 to 20 percent higher than premenopausal women of similar BMI, independent of alcohol use. This means a result of 38 U/L means something different for a 30-year-old and a 58-year-old, and your provider should interpret it in that context.

How Your Life Stage Changes the Interpretation

Your hormonal status is not a footnote. It actively changes what your AST result signals and which treatment decisions follow from it.

Reproductive Years

During the reproductive years, AST is generally stable across the menstrual cycle, though one small study of 40 healthy women found a modest rise in AST of roughly 5 to 8 U/L in the luteal phase. That variation is clinically minor but worth knowing if your blood draw was timed just before your period.

Women with polycystic ovary syndrome (PCOS) deserve a specific mention. PCOS is associated with insulin resistance, and up to 55 percent of women with PCOS have some degree of hepatic steatosis (fatty liver), which pushes AST upward. If you have PCOS and your AST is at the high end of normal or mildly elevated, your provider may order a liver ultrasound or check a full metabolic panel before starting any medication that is metabolized hepatically.

Trying to Conceive and Fertility Treatment

If you are working with a reproductive endocrinologist, your AST may be checked before starting medications like letrozole or clomiphene. Both drugs are hepatically cleared, and while liver toxicity at standard doses is rare, a baseline elevated AST above 3× the upper limit of normal (roughly 105-120 U/L) would prompt a pause before initiating treatment.

Pregnancy

AST typically decreases slightly in the first trimester and falls further in the second trimester due to hemodilution and the specific metabolic demands of pregnancy. A value above 70 U/L in pregnancy is not normal and should be evaluated urgently. HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) can cause AST to rise into the hundreds or even thousands of U/L and is a medical emergency. Intrahepatic cholestasis of pregnancy and acute fatty liver of pregnancy are two other pregnancy-specific conditions that raise AST and require prompt diagnosis.

If you are pregnant and your AST result comes back above 40 U/L, do not wait for a scheduled appointment. Contact your obstetric provider the same day.

Perimenopause and Postmenopause

The shift away from estrogen in perimenopause accelerates visceral fat accumulation and insulin resistance. The Study of Women's Health Across the Nation (SWAN) documented that liver enzyme levels, including AST, trend upward as women transition through menopause, independent of BMI changes. This is the period when NAFLD incidence in women rises sharply and begins to approach rates seen in men.

If you are in perimenopause and your AST has climbed from a previously normal baseline, your provider should consider NAFLD workup, thyroid function testing (hypothyroidism raises AST through muscle involvement), and a review of any medications or supplements you have added.

AST and the Medications Women Commonly Take

This is where your AST number becomes directly actionable. Many drugs prescribed to women across every life stage are either hepatically metabolized, hepatotoxic at high doses, or require AST monitoring as a condition of continued prescribing.

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)

GLP-1 agonists are now among the most prescribed drugs in women's metabolic health. The good news: clinical trial data from SUSTAIN-6 and LEADER show that semaglutide and liraglutide actually reduce hepatic fat and tend to lower AST in women with obesity-related liver disease. If your AST is elevated before starting a GLP-1 agonist, this class may be particularly appropriate. Your prescriber should recheck AST at 3 months to confirm the expected downward trend. A rise in AST after starting a GLP-1 agonist is uncommon and should prompt a closer look at other causes.

Statins

Statins are the most frequent reason women over 40 have an isolated, mildly elevated AST. The FDA removed the routine liver-function monitoring requirement for statins in 2012, because statin-induced true hepatotoxicity is rare (estimated at 1 in 100,000 patients). However, AST rises of 1 to 3 times the upper limit of normal are seen in a small percentage of patients and are usually transient and asymptomatic.

If your AST is between 1 and 3 times the upper limit of normal and you are on a statin, your provider will typically repeat the test in 4 to 6 weeks before making any change. If AST exceeds 3× the upper limit of normal on two consecutive measurements, statin dose reduction or a switch to a different statin is standard practice.

Metformin

Metformin is prescribed extensively in women with PCOS, prediabetes, and type 2 diabetes. Hepatotoxicity from metformin is rare, but because the women most likely to take it (those with PCOS or metabolic syndrome) already have an elevated baseline AST, the two signals can be hard to untangle. A 2020 analysis in Diabetes Care confirmed that metformin does not cause clinically significant AST elevations at standard doses (up to 2,000 mg/day) and may modestly lower AST in women with NAFLD.

Hormone Therapy and Oral Contraceptives

Oral estrogens are metabolized first-pass through the liver. High-dose estrogen-containing oral contraceptives have been associated with mild AST elevations in a subset of users, though this is far less common with modern low-dose formulations. Transdermal estrogen (patches, gels) bypasses first-pass hepatic metabolism and is far less likely to affect AST. Women with pre-existing elevated AST who need hormone therapy should generally be offered transdermal estradiol rather than oral estrogen for this reason.

Progestogens at high doses (such as megestrol acetate for appetite stimulation in oncology patients) can raise AST. Standard contraceptive and menopausal doses do not carry this risk.

Levothyroxine

Both over- and under-treatment of hypothyroidism can raise AST. Hypothyroidism causes myopathy (muscle breakdown), releasing AST from muscle tissue. Hyperthyroidism causes accelerated hepatic metabolism and can cause mild liver enzyme elevation. The American Thyroid Association guidelines recommend checking liver enzymes if a patient on levothyroxine develops symptoms of liver injury, but routine monitoring is not required at stable doses.

Weight-Loss Medications Beyond GLP-1s

Orlistat, a fat-absorption inhibitor, has been associated with rare but serious hepatotoxicity. The FDA has received reports of severe liver injury in orlistat users, and baseline and periodic AST monitoring is advisable. Women taking orlistat who develop nausea, jaundice, or right upper quadrant pain should have AST checked immediately.

The AST:ALT Ratio: Reading the Pair, Not Just the Number

A practical framework for reading your own results: think of AST and ALT as two detectives at a crime scene. ALT is more liver-specific, so when ALT rises alongside AST, the injury is almost certainly hepatic. When AST rises without a proportional ALT rise, look at muscle, thyroid, or heart.

| AST:ALT Ratio | Most Likely Cause | |---|---| | <1 (ALT higher) | NAFLD, viral hepatitis, medication effect | | 1 to 2 | Mixed: early alcoholic liver disease, steatohepatitis | | >2 | Alcoholic liver disease, cirrhosis | | AST elevated, ALT normal | Muscle injury, hypothyroidism, hemolysis |

Women with PCOS or obesity-related NAFLD most often fall into the <1 ratio category. Women whose AST elevation traces to thyroid disease or intense exercise often have a normal ALT and an isolated AST elevation, which is clinically reassuring but still worth explaining to your provider.

What Happens to Your Treatment When AST Is High

Your AST result does not live in isolation. It feeds directly into prescribing decisions through a tiered framework most hepatologists and prescribers use:

Mild Elevation (1 to 3× Upper Limit of Normal, Roughly 40 to 120 U/L)

Your provider will typically continue the current medication and recheck in 4 to 6 weeks. They may add an investigation: repeat fasting lipids, HbA1c, hepatitis B and C serology, thyroid-stimulating hormone, and a liver ultrasound if not done in the past year.

Moderate Elevation (3 to 10× Upper Limit of Normal, Roughly 120 to 400 U/L)

This tier triggers a medication review. Any recently started drug is a suspect. Most prescribers will hold or reduce the dose of any hepatotoxic drug and recheck AST in 2 weeks. GLP-1 agonists are less commonly the culprit and may actually be part of the solution if NAFLD is the driver.

Severe Elevation (>10× Upper Limit of Normal, Above 400 U/L)

This is a clinical emergency. Any potentially hepatotoxic medications are stopped immediately. The Drug-Induced Liver Injury Network (DILIN) criteria, developed in part from NIH-funded U.S. Data, define this threshold as grounds for urgent hepatology referral regardless of symptoms.

How to Lower a High AST

Lowering AST means addressing its root cause. There is no supplement or medication that lowers AST directly without treating what raised it.

Dietary Changes With Evidence

A Mediterranean-style diet reduced hepatic fat and ALT by a statistically significant margin in a randomized trial of adults with NAFLD. AST followed the same downward trend. For women with PCOS, the dietary changes that improve insulin resistance (reducing refined carbohydrates, increasing fiber) also tend to reduce AST over 3 to 6 months.

Alcohol is the single fastest modifiable driver of AST in otherwise healthy women. Because women have lower gastric alcohol dehydrogenase activity than men, they absorb a higher proportion of ingested alcohol, meaning equivalent alcohol intake produces higher blood alcohol concentrations and more hepatic stress in women than in men. Even moderate drinking (7 or more drinks per week) can push AST above normal in women who are otherwise healthy.

Exercise

Aerobic exercise reduces hepatic fat and lowers liver enzymes. A 2012 meta-analysis in the Journal of Hepatology found that 150 to 200 minutes of moderate-intensity aerobic exercise per week reduced AST by an average of 11 U/L in people with NAFLD. Resistance training showed a similar but slightly smaller effect.

Paradoxically, very intense acute exercise (long-distance running, heavy weight sessions) can temporarily raise AST from muscle breakdown. If you are an athlete, time your AST draw at least 48 hours after a hard workout.

Weight Loss

In women with obesity-related NAFLD, a 7 to 10 percent reduction in body weight reliably lowers AST. A landmark NASH Clinical Research Network trial showed that sustained weight loss of at least 7 percent over 48 weeks led to histological improvement in liver disease and significant reductions in AST in women and men alike.

Treating the Underlying Condition

For women with PCOS, treating insulin resistance with metformin or a GLP-1 agonist often normalizes AST as a downstream effect. For women with hypothyroidism, optimizing levothyroxine dose normalizes the myopathic component of AST elevation within 6 to 8 weeks of reaching a therapeutic TSH. The American Thyroid Association recommends a target TSH of 0.4 to 4.0 mIU/L for most nonpregnant adults, with narrower targets in specific populations.

Pregnancy, Lactation, and AST Monitoring

This section is required reading if you are pregnant, postpartum, or planning a pregnancy while on any medication that requires AST monitoring.

In Pregnancy

Normal AST in pregnancy is the same or slightly lower than nonpregnant ranges in the first trimester. By the third trimester, AST should still be below 40 U/L. Any elevation above that needs same-day clinical evaluation, because the differential includes three obstetric emergencies: HELLP syndrome, acute fatty liver of pregnancy, and intrahepatic cholestasis of pregnancy. ACOG Practice Bulletin 222 specifies AST as part of the laboratory criteria for severe preeclampsia with severe features.

Most medications that require routine AST monitoring (statins, orlistat) are contraindicated in pregnancy and should be stopped before conception or as soon as pregnancy is confirmed. Statins carry an FDA pregnancy category X designation for fetal risk. GLP-1 agonists (semaglutide, tirzepatide) are also not recommended in pregnancy; FDA labeling for semaglutide advises stopping the drug at least 2 months before a planned conception, given the drug's long half-life.

Postpartum and Lactation

AST returns to pre-pregnancy levels within 6 to 8 weeks postpartum in uncomplicated deliveries. Postpartum thyroiditis, which affects 5 to 10 percent of women in the first year after delivery, can cause transient AST elevation through the thyrotoxic phase. If your AST is mildly elevated at your 6-week or 3-month postpartum visit, thyroid function testing is a reasonable first step.

For breastfeeding women: most medications that are stopped during pregnancy (statins, weight-loss drugs) remain contraindicated during lactation due to transfer into breast milk. Metformin transfers into breast milk in small amounts and is generally considered compatible with breastfeeding by most guidelines, though your provider should review this in the context of your specific situation.

Who Should Be Monitored More Closely

Not every woman needs frequent AST checks. But certain profiles warrant more vigilance:

• Women with PCOS and BMI >30 kg/m² (high NAFLD risk)
• Perimenopausal and postmenopausal women newly started on oral hormone therapy
• Women taking statins plus a fibrate (combination raises hepatotoxicity risk)
• Women on long-term oral contraceptives with additional liver disease risk factors
• Women with a personal or family history of autoimmune hepatitis (more common in women than men, with a female-to-male ratio of approximately 4:1)
• Women taking any herbal supplement containing kava, green tea extract, or black cohosh, all of which have documented hepatotoxic potential

Black cohosh deserves a specific call-out. It is widely used for perimenopausal symptoms, and the National Institutes of Health Office of Dietary Supplements has documented case reports of liver injury linked to its use. If you are taking black cohosh and your AST is elevated, your provider should consider stopping it and rechecking in 4 to 6 weeks.

What a Low AST Means

A very low AST (below 10 U/L) is less often discussed but clinically meaningful. Possible causes include:

• Vitamin B6 (pyridoxine) deficiency, because AST requires B6 as a cofactor
• Severe malnutrition
• Uremia in advanced kidney disease
• Some laboratory assay errors

In women who are severely restricting calories (as sometimes seen in eating disorders or very aggressive weight-loss interventions), a paradoxically low AST may reflect nutrient depletion rather than liver health. This is an area where the evidence base specific to women is thin; most data on low AST comes from mixed-sex populations in renal disease literature. If your AST is below 10 U/L, your provider should look at a full nutrition panel, including B6, albumin, and pre-albumin.

The Evidence Gap: What We Know and Don't Know About AST in Women

Women have been systematically under-represented in hepatology trials. The DILIN prospective study, which forms the evidentiary basis for most drug-induced liver injury thresholds in the U.S., enrolled approximately 59 percent women in its final cohort, which is better than many drug trials but still not disaggregated by hormonal status or life stage. We do not have strong, women-specific data on how AST thresholds for medication decisions should be adjusted across the menstrual cycle, across perimenopause, or in women on combined hormonal contraception.

As WomanRx clinical reviewer Dr. Elena Vasquez, MD, notes: "The liver enzyme cutoffs we use to make prescribing decisions were largely validated in populations without systematic hormonal-status stratification. A postmenopausal woman with a TSH of 8 and an AST of 45 is a completely different clinical picture from a 30-year-old with an AST of 45 after a half-marathon. We have to stop reading these numbers as if the woman's biology is a footnote."

This honesty matters. If your provider tells you your AST is "fine" based on a generic reference range without considering your life stage, your PCOS, your thyroid status, or your recent exercise, that interpretation may be incomplete.